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Abstract
Bisphosphonates suppress bone remodeling activity, increase bone volume, and significantly reduce
fracture risk in individuals with osteoporosis and other metabolic bone diseases. The objectives of
the current study were to develop a mathematical model that simulates control and 1 year
experimental results following bisphosphonate treatment (alendronate or risedronate) in the canine
fourth lumbar vertebral body, validate the model by comparing simulation predictions to 3 year
experimental results, and then use the model to predict potential long term effects of bisphosphonates
on remodeling and microdamage accumulation. To investigate the effects of bisphosphonates on
bone volume and microdamage, a mechanistic biological model was modified from previous versions
to simulate remodeling in a representative volume of vertebral trabecular bone in dogs treated with
various doses of alendronate or risedronate, including doses equivalent to those used for treatment
of post-menopausal osteoporosis in humans. Bisphosphonates were assumed to affect remodeling
by suppressing basic multicellular unit activation and reducing resorption area. Model simulation
results for trabecular bone volume fraction, microdamage, and activation frequency following 1 year
of bisphosphonate treatment are consistent with experimental measurements. The model predicts
that trabecular bone volume initially increases rapidly with 1 year of bisphosphonate treatment, and
continues to slowly rise between 1 and 3 years of treatment. The model also predicts that
microdamage initially increases rapidly, 0.5 to 1.5-fold for alendronate or risedronate during the first
year of treatment, and reaches its maximum value by 2.5 years before trending downward for all
dosages. The model developed in this study suggests that increasing bone volume fraction with long
*Please address all correspondence to: Scott J. Hazelwood, PhD, Biomedical and General Engineering Department, California
Polytechnic State University, San Luis Obispo, CA 93407, Phone: 1-805-756-6304, Fax: 1-805-756-6424, Email: shazelwo@calpoly.edu.
Conflict of interest statement: MRA and DBB have received financial support from Eli Lilly, The Alliance for Better Bone Health
(Procter and Gamble), and Amgen. In addition, DBB serves as an advisor for Eli Lilly and Merck, and as a speaker for Eli Lilly, The
Alliance for Better Bone Health, Amgen, Roche, and GlaxoSmithKline. XW, AME, RBM, and SJH disclose that they do not have conflicts
of interest regarding the work presented in this manuscript.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting
proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could
affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
J Biomech. Author manuscript; available in PMC 2010 May 11.
Published in final edited form as:
J Biomech. 2009 May 11; 42(7): 938–944. doi:10.1016/j.jbiomech.2008.07.039.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
term bisphosphonate treatment may sufficiently reduce strain and damage formation rate so that
microdamage does not accumulate above that which is initiated in the first two years of treatment.
Keywords
Bisphosphonate; bone remodeling; BMU; alendronate; risedronate; simulation; canine;
microdamage
Introduction
Bisphosphonates (BPs) are anti-resorptive drugs that suppress bone remodeling, increase bone
volume and bone mineral density, and are used to treat post-menopausal osteoporosis and other
bone fragility disorders (Rodan and Fleisch, 1996; Chavassieux et al., 1997; Tonino et al.,
2000; Ding et al., 2003; Dufresne et al., 2003; Recker et al., 2005). At the tissue level in humans,
BP treatment is associated with decreased bone resorption and turnover (Storm et al., 1993;
Rodan and Fleisch, 1996; Eriksen et al., 2002) and therefore provides a transient increase in
bone volume (filling of pre-existing remodeling spaces). This may be followed by a further
trend to increase bone volume by reducing the amount of bone resorbed relative to that formed
by basic multicellular units (BMUs) (Boyce et al., 1995). In post-menopausal women, BPs
reduce fracture risk by improving the structural properties of bone (Delmas, 2000) and
increasing the degree of mineralization (Boivin et al., 2000). However, BP treatment also
results in significant microdamage accumulation and a reduction in bone toughness in canine
vertebrae (Mashiba et al., 2001; Komatsubara et al., 2003; Allen et al., 2006; Allen and Burr,
2007). The microdamage accumulation is due, at least in part, to decreased remodeling, which
is the only mechanism in bone to remove fatigue damage (Burr et al., 1985; Mori and Burr,
1993). These observations, some having positive and others negative implications in bone,
indicate the need for a better understanding of BP effects on bone remodeling, structure, and
material properties.
While long term BP studies have focused on alterations to bone mineral density and bone
turnover (Miller et al., 1997; Tonino et al., 2000; Bone et al., 2004; Ste-Marie et al., 2004;
Borah et al., 2006; Zoehrer et al., 2006), their effects on microdamage accumulation have not
been studied beyond three years of treatment (Forwood et al., 1995; Hirano et al., 2000;
Mashiba et al., 2000; Mashiba et al., 2001; Komatsubara et al., 2003; Day et al., 2004;
Komatsubara et al., 2004; Mashiba et al., 2005; Allen et al., 2006, Allen and Burr, 2007).
Results from canine studies have documented microdamage increases in the vertebral body,
rib, and ilium following 1 to 3 years of BP treatment, but these changes were compensated for
by increases in bone mass and structural properties, including ultimate load and stiffness (Allen
and Burr, 2007). However, some of these studies also documented significant reductions in
bone toughness, the intrinsic ability of the tissue to resist fracture. Since BP treatment in patients
with osteoporosis now extends 10 years or more, the long term effects of BPs on microdamage
accumulation and bone fragility are of clinical interest.
In the present study, we develop a mathematical model to explore the long term effects of BP
treatment on bone. We have previously developed computational models simulating bone
mechanics and remodeling in a representative volume of bone (Martin, 1995; Hazelwood et
al., 2001; Nyman et al., 2004; Nyman et al., 2006). These models simulate BMU activation
and remodeling in response to mechanical loading and fatigue microdamage. Our overall goal
in developing these mathematical models is to simulate the long term effects of BPs on
remodeling and microdamage accumulation in current animal models and, ultimately, in
humans. As an initial step, our approach in the current study is to develop a model of remodeling
in a representative volume of trabecular bone based on control and 1 year experimental results
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following BP treatment in the canine fourth lumbar vertebral body (Allen et al., 2006), and
subsequently to test its predictions against data from a 3 year alendronate study (Allen and
Burr, 2007). Then, in an effort to understand long term bisphosphonate treatment effects over
periods similar to those for clinical use in humans, we examine model predictions after 10 years
of simulated treatment.
Methods
The control and 1 year data used for model development were from skeletally mature female
beagles treated daily with saline vehicle or one of three doses of alendronate (ALN: 0.10, 0.20,
or 1.00 mg/kg/day) or risedronate (RIS: 0.05, 0.10, or 0.50 mg/kg/day) (Allen et al., 2006).
The middle doses of ALN and RIS correspond to the clinical treatment dose, on a mg/kg basis,
for post-menopausal osteoporosis. The lower dose of ALN corresponds to the preventative
dose for osteoporosis, while the higher dose of both ALN and RIS are approximately equivalent
to those used for treatment of Paget's disease. In that study, trabecular bone mineral density
(BMD, g/cm3), volume fraction (BV/TV), activation frequency (Ac.f), and microdamage
(crack surface density or Cr.S.Dn) in the fourth lumbar vertebra (L4) were quantified.
A previous bone remodeling algorithm (Hazelwood et al., 2001; Nyman et al., 2004) was
modified to simulate remodeling in a 1 cm3 volume of canine L4 vertebral trabecular bone
under uniaxial cyclic loading. The model describes histomorphometric variables governing
bone mechanical properties (Table 1). The cancellous bone structure was assumed to be
isotropic with a uniform bone volume fraction, BV/TV. The continuum-level elastic modulus
(E) was assumed to be related to BV/TV by
(1)
where E0 = 19,735 MPa and b = 2.4217 were obtained by fitting experimental data from control
and 1 year BP-treated dogs to Eq. 1 (Table 2). Peak strain was calculated as
(2)
where σ is the peak stress applied during cyclic loading.
A loading potential, Φ, was defined to characterize the mechanical environment as it affects
remodeling (Hazelwood et al., 2001):
(3)
where RL is the loading frequency (assumed to be constant at 3000 cycles per day), and q = 4
adjusts the relative contribution of peak strain and loading frequency to the loading potential.
Microdamage
Microdamage (Cr.S.Dn) was defined as cumulative microcrack length per unit cross-sectional
area of bone (mm/mm2). The damage formation rate was assumed to be proportional to the
loading potential,
Wang et al. Page 3
J Biomech. Author manuscript; available in PMC 2010 May 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
(4)
where kD is chosen to make the damage formation and removal rates equal under steady state
conditions (Hazelwood et al., 2001).
The fatigue microdamage removal rate was modeled as (Martin, 1995)
(5)
where Ac.f is the BMU activation frequency, Rs.Ar is the resorption space area, and Fs is a
“steering factor” to account for targeted damage removal (Martin, 1985). Hence, the net
damage accumulation rate is
(6)
Bone volume fraction
The time rate of change of bone volume fraction, d(BV/TV)/dt, was assumed to be a function
of the mean bone resorption (Rs.Ar/Rs.P) and refilling (FAr/FP) rates within individual BMUs,
and the mean densities of resorbing (N.Rs.BMU) and refilling (N.F.BMU) BMUs (Martin,
1985):
(7)
(8)
(9)
where Rs.Ar and FAr are the mean resorption and refilling areas and Rs.P and FP are the mean
resorption and refilling periods, respectively, of individual BMUs (Table 2). The shape of the
BMU resorption cavity was modeled as a semi-ellipse having a mean cross-sectional area of
0.014 mm2 as measured from the control dogs (previously unpublished data (Allen et al.,
2006)).
BMU activation frequency
BMU Ac.f (BMUs/mm2/day) was assumed to be a function of disuse, microdamage, and the
available surface area for remodeling, BS/TA. This leads to the equation
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(10)
(11)
(12)
where Ac.fdamage and Ac.fdisuse represent the BMU activation frequencies associated with
microdamage and disuse, respectively, and are assumed to be independent remodeling
responses. Specific surface area was determined from BV/TV using an empirical relationship,
(13)
normalized by the maximum value, (BS/TA)max = 4.191 mm-1 (Hazelwood et al., 2001).
To compare simulation predictions with experimental results, the annual activation frequency
(Ac.fyear, BMU/year) was calculated as (Nyman et al., 2004)
(14)
where Md.S.Le is the mean mineralized length of a BMU's active surface (Table 2).
Bisphosphonate effects
BP treatment was assumed to (1) suppress BMU activation frequency (Storm et al., 1993;
Chavassieux et al., 1997; Chavassieux et al., 2000; Eriksen et al., 2002) and (2) reduce
resorption cavity depth (Boyce et al., 1995). A potency variable, P, was defined to quantify
the BP's ability to suppress remodeling activation (Nyman et al., 2004):
(15)
where N.Rs.BMU is the number of resorbing BMUs, Pmax = 1 is the fully suppressed potency,
and τs is a suppression coefficient (Table 3). The activation frequency was suppressed by
multiplying Ac.f by (1-P), where P has a value between 0 and 1. Resorption cavity area (Rs.Ar)
was also assumed to be reduced, depending on the type and dosage of BP treatment (Nyman
et al., 2004). A refilling coefficient describing the balance between bone formed and resorbed
at each resorption site was defined as
Wang et al. Page 5
J Biomech. Author manuscript; available in PMC 2010 May 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
(16)
where Rs.Ar(BP) is the reduced resorption cavity area dependent on the BP administered and
dosage (Table 2).
Numerical Simulation
All simulations were performed in MATLAB (MathWorks, Natick, MA). The model was
implemented using a time step of 1 day. An equilibrium status of trabecular bone remodeling
that matched the experimental control data for canine vertebral trabecular bone was obtained
first (Table 4). For a BV/TV of 22.3% (Allen et al., 2006) in a 1 cm3 representative volume of
trabecular bone, it was found that a peak cyclic stress of σ = 0.265 MPa produces steady state
values for the principal outcome variables Ac.f, Cr.S.Dn, and BV/TV similar to the remodeling
data of the control dogs. Then, using the equilibrium condition as the baseline, the model was
used to find values of the bisphosphonate variables τs and CF that matched the 1 year canine
experimental data (Tables 3 and 4). Because BPs suppress bone turnover soon after treatment
initiation (Porras et al., 1999), their effects were assumed to begin immediately.
The simulation then was carried out for 3 years of BP treatment and results were compared to
recent 3 year experimental data available for the fourth lumbar vertebral body in canines at the
middle (0.20 mg/kg/day) and high (1.00 mg/kg/day) doses of alendronate treatment (Allen and
Burr, 2007). Finally, the model was used to predict the effects on remodeling and damage
accumulation after 10 years of BP treatment to provide an understanding of longer term
bisphosphonate use at periods similar to those for human osteoporosis patients.
Comparisons of simulation predictions to experimental results were made by examining the
similarity of the values in comparison to the measured standard deviation and by a one sample
t-test (p<0.05 significant) with the hypothesis that the simulation values represent the
experimental means.
Results
As expected, the simulated results following 1 year of BP treatment are consistent with
experimental measurements (Table 4). At 1 year, the model predicts that the high dose of ALN
will suppress Ac.f by 85% compared to 62% for the low dose. The equivalent values predicted
for RIS are much more widely spread at 87% and 39%, respectively (Fig. 1). At the doses used
for treatment of human post-menopausal osteoporosis, ALN (0.20 mg/kg/day) and RIS (0.10
mg/kg/day) reduce the number of active BMUs per year to 0.45 and 0.65, respectively. The
model predicts that 1 year of ALN treatment increases BV/TV approximately 13% (Fig. 2)
compared to 9.7 to 13% for RIS, depending on dose (Fig. 3). Microdamage is predicted to
reach its maximum within the first year for the low dose of ALN (Fig. 2) or RIS (Fig. 3)
treatment. For the middle and high doses of ALN and RIS, Cr.S.Dn is predicted to increase
rapidly by 46 to 155% after 1 year of treatment. All predicted Ac.f, BV/TV, and Cr.S.Dn values
at 1 year of treatment are within one standard deviation of their corresponding experimental
measurements. The t-test analysis indicates a similarity between experimental results and their
corresponding model predictions for all values at 1 year of BP treatment except for Ac.f for
ALN at the high dose (p=0.03) and Cr.S.Dn for RIS at the low dose (p=0.02).
The model predicts modest additional increases in bone volume fraction between 1 and 3 years
of treatment (Table 5). For ALN, the percent increase in BV/TV from the 1 year predictions
ranges from 4.2% at the low dose to 5.2% at the high dose (Fig. 2). For RIS, the increase in
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BV/TV ranges from 1.5% to 4.5% between the low and high doses, respectively (Fig. 3). In
addition, the simulation predicts slight changes in Ac.f for ALN (-0.72% to -2.6%) and RIS
(-1.5% to 3.4%) between 1 and 3 years of treatment.
Due to the bisphosphonate-induced inhibition of remodeling, resulting in a greater initial
decline in the damage removal rate than the damage formation rate (Fig. 4), microdamage is
predicted to increase during the first year of treatment. Within three years, Cr.S.Dn reaches its
maximum value and thereafter trends downward at greatly varying rates depending on the
dosage of ALN or RIS (Figs. 2 and 3). Compared to 1 year of treatment, the model predicts a
26% decrease in Cr.S.Dn after 3 years of low dose (0.05 mg/kg/day) RIS treatment. Under the
high dose RIS regimen, Cr.S.Dn continues to increase throughout the second year and starts
to diminish in the third year of treatment, reaching a damage burden at 3 years that is 20%
above that at 1 year. The dynamics are similar for ALN, and for both bisphosphonates the
maximum amounts of Cr.S.Dn predicted at 3 years increase with increasing dosage. For both
ALN and RIS, the lowest dose allows a faster return to a low damage burden compared to the
higher doses.
Predicted BV/TV, Cr.S.Dn, and Ac.f results at 3 years of treatment are at or within one standard
deviation of the corresponding experimental measurements in all cases except for Ac.f at the
middle dose of ALN which is 2.8 standard deviations different. The statistical analysis indicates
significant differences for experimental results compared to predicted values for the middle
dose (0<p<0.02) but similarities for all values at the high dose after 3 years of treatment.
Depending on dose, the model predicts long term bisphosphonate treatment for 10 years to
produce BV/TV increases of 20 to 29% for ALN (Fig. 2a) and 11 to 27% for RIS (Fig. 3a)
compared to controls. Running the present model out to 10 years of treatment produces steady
state values of Ac.f after approximately 2.5 years for RIS (Fig. 3c) and 3.5 years for ALN (Fig.
2c) that are 64 to 86% below the untreated controls for ALN and 36 to 88% below controls for
RIS depending on dose. Microdamage accumulation (Figs. 2b and 3b) is also dose dependent
and reaches its peak between 0.3 and 2.5 years (more quickly for lower doses). Microdamage
reaches a steady state value (0.0093 mm/mm2) slightly below the untreated controls after 8
years of ALN treatment for the low dose. After 10 years of the high dose RIS treatment, Cr.S.Dn
(0.0233 mm/mm2) is greater than those of the middle (0.0105 mm/mm2) and low (0.0100 mm/
mm2) dose treatments. With the middle and high doses of ALN or the high dose of RIS, Cr.S.Dn
continues to decline even after 10 years of treatment.
Discussion
Bisphosphonates are widely used to treat human post-menopausal osteoporosis and have well-
established anti-fracture efficacy. Experiments on canines involving 1 year of bisphosphonate
treatment at various doses (including those used to treat post-menopausal osteoporosis) show
suppressed bone remodeling activity; increased bone volume fraction, mineralization, stiffness,
and microdamage accumulation; and reduced bone toughness (Mashiba et al., 2001;
Komatsubara et al., 2003; Allen et al., 2006). The goal of the current study was to develop a
computational model to simulate the effects of BPs on bone remodeling based on 1 year
experimental data from canine vertebrae and then examine results simulating long term BP
use.
For varying doses of ALN or RIS, our model predicts a sharp decline in activation frequency
during the first two months of treatment. Subsequently, Ac.f increases slightly, reaching a new
equilibrium after 2 to 5 years of treatment. The degree of Ac.f decline is consistent with 1 year
experimental data (Allen et al., 2006), and its predicted long term steady state results are dose
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dependent, with the three doses of RIS having a wider variation in long term results compared
to the ALN doses.
In the simulation, microdamage accumulates rapidly within the first three years of BP
treatment. Although the microdamage formation rate initially decreases sharply as a result of
increases in BV/TV, which reduces the strain level in the representative bone volume, the initial
decrease in the damage removal rate due to the Ac.f reduction is greater (Fig. 4). Then Ac.f
and, subsequently, the damage removal rate begin to recover. Eventually, within 0.3 to 2.5
years depending on dose, the damage removal rate surpasses the diminished damage formation
rate, and the burden of damage due to remodeling inhibition declines. These data predict that
microdamage accumulation will be of greatest concern in the short-term following the initiation
of BP treatment, prior to the point where bone volume increases sufficiently to reduce local
strain. This is consistent with data from the 1 and 3 year experiments that show a significant
increase in damage at 1 year but no difference between 1 and 3 years of ALN treatment (Allen
and Burr, 2007). These results suggest that the reduced level of remodeling may be sufficient
to control microdamage accumulation during long term BP treatment. The model predicts that
ultimately, after 8 years of ALN treatment for the low dose, a new equilibrium is reached with
a damage burden about 31% lower than that of the untreated baseline controls. For RIS the
return to a steady state requires approximately 3 to 8 years for the low and middle doses, with
damage at 10 years predicted to be 26% less for the low dose and 22% less for the middle dose
relative to baseline controls.
One of the strengths of the current study is the ability to compare the simulation results with
those from a well-designed experiment with control animals to represent the equilibrium status
before BP treatment. Data on the effects of BP treatment on BV/TV, Ac.f, and Cr.S.Dn provide
a foundation for defining the “dose-response coefficients” for the effects of the
bisphosphonates examined. That the present model reasonably predicts the 3 year experimental
work demonstrates the appropriateness of the coefficients chosen for the simulation and forms
a basis to explore BP effects over time periods consistent with post menopausal life spans.
However, the present work clearly has significant limitations. The bone remodeling process is
simplified in the model. For example, variability in the size and shape of resorption cavities,
and many other aspects of the remodeling process, are not represented in the present computer
simulation. Furthermore, the present model only simulates bone volume fraction as governed
by remodeling within trabecular bone, and does not consider the microarchitecture of trabecular
bone or the effects of cortical bone. Neither does it consider bone modeling activities that may
affect bone fragility (Frost, 1998). The effects of remodeling are only considered with regard
to elastic modulus; certainly bisphosphonates are expected to affect strength and toughness as
well.
Experimental results show increased trabecular bone stiffness after BP treatment, but no
difference in elastic modulus, ultimate load, or ultimate stress (Allen et al., 2006). However,
our simulation results indicate 1 year of BP treatment increases not only BV/TV but also elastic
modulus in ALN- and RIS-treated animals compared to controls. One explanation for this
discrepancy is that the effects of BP treatment on the degree of bone mineralization (Allen et
al., 2006), which significantly affects elastic modulus and other mechanical properties (Moore
and Gibson, 2002; Wang and Niebur, 2006), was not considered in the model.
Over time, many of these limitations may be overcome by developing more detailed models
in conjunction with ongoing experimental work and the accumulation of human data. In the
meantime, the present simulation and experimental results suggest that the effects of
bisphosphonates on bone remodeling may not lead to bone fragility associated with
microdamage accumulation, and are consistent in that regard with ten year alendronate
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treatment data for humans (Bone et al., 2004). Further work is needed, however, before this
and other clinical questions can be answered.
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Figure 1.
Ac.fyear decreases in relation to control after 1 year of ALN and RIS treatment. The error bars
represent one standard deviation. CON represents the control data. ALN 0.10 refers to an
alendronate dose of 0.10 mg/kg/day, etc.
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Figure 2.
Predictions for BV/TV, Cr.S.Dn and Ac.f during 3 years of ALN treatment. Time=0 represents
the beginning of ALN treatment. ALN 0.10 refers to an alendronate dose of 0.10 mg/kg/day,
etc. The error bars represent ± 1 standard deviation.
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Figure 3.
Predictions for BV/TV, Cr.S.Dn and Ac.f during 3 years of RIS treatment. Time=0 represents
the beginning of RIS treatment. RIS 0.05 refers to a risedronate dose of 0.05 mg/kg/day, etc.
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Figure 4.
In the dogs subjected to the middle dose of ALN (0.20 mg/kg/day), the simulation predicts that
microdamage formation and removal rates initially decrease sharply after BP administration.
As the microdamage formation rate continues to decline over time due to further increases in
BV/TV, the damage removal rate recovers as a result of increases in Ac.f. As the microdamage
removal rate surpasses the formation rate, damage accumulation declines. Similar patterns were
observed for all doses of ALN and RIS.
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Table 1
Model state variables
State variable
E Elastic modulus (MPa)
BV/TV Volume fraction
N.Rs.BMU Number of resorbing BMUs (# BMU/mm2)
N.F.BMU Number of refilling BMUs (# BMU/mm2)
Ac.f BMU activation frequency (# BMU/mm2/day)
Ac.fyear BMU activation frequency (# BMU/year)
BS/TA Bone surface area per section area
Cr.S.Dn Microdamage (mm/mm2)
σ Peak stress of cyclic compressive loading
ε Peak strain of cyclic compressive loading
Φ Mechanical stimulus (cycles per day, cpd)
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Table 2
Model constants
Constant Values Source
E0 Tissue modulus (MPa) 19735 Calculated*
b Modulus-BV/TV exponent 2.4217 Calculated*
Rs.Ar Resorption area, mm2 0.01395 Measured*
FAr Refilling area, mm2 0.01395 Assumed equal to Rs.Ar
CF Ratio of FAr to Rs.Ar(BP) 1.45-2 -
Rs.Ar (BP) BP treatment resorption area, mm
2 FAr/CF -
E.De Erosion cavity depth, mm 0.0667 Measured*
E.Wi Erosion cavity width, mm 0.293 Measured*
Md.S.Le Mean mineralized bone surface length, mm 0.1935 Measured*
Rs.P Resorption period, days 10 Measured*
Rv.P Reversal period, days 5 (Nyman et al., 2004)
FP Refilling period, days 44 Measured*
kD Damage rate coefficient, mm/mm
2 11×105 Estimated **
q Damage rate exponent 4 (Whalen et al., 1988;
Hazelwood et al., 2001)
RL Loading rate, cpd 3000 (Hazelwood et al., 2001)
Fs Damage removal specificity factor 20 Estimated **
Cr.S.Dn0 Threshold damage, mm/mm
2 0.01 Estimated **
Ac.f0 Threshold BMU act. freq., BMUs/mm
2/day 0.08 Estimated **
Φ0 Threshold mechanical stimulus, cpd 1.875×10-10 (Beaupre et al., 1990)
Ac.fmax Max. BMU act. freq., BMUs/mm
2/day 0.50 (Frost, 1969; Schaffler et al.,
1995)
kb Act. freq. dose-response coefficient, cpd
-1 6.5×1010 (Hazelwood et al., 2001)
kc Act. freq. dose-response coefficient, cpd 9.4×10
-11 (Hazelwood et al., 2001)
kr Act. freq. coefficient -1.6 (Hazelwood et al., 2001)
Pmax Maximum potency 1 (Nyman et al., 2004)
τs Coefficient 1-50 (Nyman et al., 2004)
*
Previously unpublished data measured or calculated from the specimens of Allen et al. (2006).
**
Parameters estimated in the model simulation to produce steady state values for Ac.f, Cr.S.Dn, and BV/TV similar to the remodeling data for controls
and 1 year experiments.
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Table 3
Sensitivity analysis of bisphosphonate effects simulated by the model
Bisphosphonate Dosage
(mg/kg/day)
Suppression Coeff.
τs
Refilling Coeff.
CF
ALN 0.10 11.3 1.70
0.20 18.8 1.80
1.00 38 2.00
RIS 0.05 5 1.45
0.10 11 1.65
0.50 50 2.00
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Table 4
Model predictions and experimental measurements in the canine vertebral body after 1 year of ALN or RIS treatment.
Treatment Variable Simulation Experiment
Control BV/TV 0.223 0.219 ± 0.031
Cr.S.Dn (mm/mm2) 0.0135 0.0068 ± 0.0073
Ac.fyear (# BMUs/year) 1.70 1.89 ± 0.84
1 year ALN
0.10 mg/kg/day
BV/TV 0.252 0.257 ± 0.052
Cr.S.Dn 0.0198 0.0210 ± 0.0178
Ac.fyear 0.64 0.66 ± 0.38
1 year ALN
0.20 mg/kg/day
BV/TV 0.252 0.264 ± 0.036
Cr.S.Dn 0.0252 0.0250 ± 0.0140
Ac.fyear 0.45 0.54 ± 0.24
1 year ALN
1.00 mg/kg/day
BV/TV 0.252 0.259 ± 0.044
Cr.S.Dn 0.0321 0.0322 ± 0.0212
Ac.fyear 0.26 0.45 ± 0.27
1 year RIS
0.05 mg/kg/day
BV/TV 0.244 0.254 ± 0.038
Cr.S.Dn 0.0140 0.0199 ± 0.0075
Ac.fyear 1.04 1.13 ± 0.65
1 year RIS
0.10 mg/kg/day
BV/TV 0.250 0.231 ± 0.038
Cr.S.Dn 0.0197 0.0200 ± 0.0121
Ac.fyear 0.65 0.65 ± 0.38
1 year RIS
0.50 mg/kg/day
BV/TV 0.251 0.263 ± 0.037
Cr.S.Dn 0.0344 0.0370 ± 0.0195
Ac.fyear 0.21 0.31 ± 0.31
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Table 5
Model predictions for changes in the canine vertebral body after 3 years of ALN or RIS treatment
Treatment Variable Simulation Change From 1
Year Simulation
Result (%)
Experiment*
3 year ALN
0.10 mg/kg/day
BV/TV 0.262 4.21 -
Cr.S.Dn
(mm/mm2)
0.0128 -35.35 -
Ac.fyear
(# BMU/year)
0.62 -2.25 -
3 year ALN
0.20 mg/kg/day
BV/TV 0.264 4.84 0.245 ± 0.017
Cr.S.Dn 0.0193 -23.41 0.0376 ± 0.0223
Ac.fyear 0.43 -2.58 0.328 ± 0.037
3 year ALN
1.00 mg/kg/day
BV/TV 0.265 5.15 0.258 ± 0.017
Cr.S.Dn 0.0338 5.30 0.0493 ± 0.0293
Ac.fyear 0.26 -0.72 0.319 ± 0.094
3 year RIS
0.05 mg/kg/day
BV/TV 0.248 1.47 -
Cr.S.Dn 0.0103 -26.42 -
Ac.fyear 1.08 3.43 -
3 year RIS
0.10 mg/kg/day
BV/TV 0.259 3.59 -
Cr.S.Dn 0.0133 -32.49 -
Ac.fyear 0.64 -1.49 -
3 year RIS
0.50 mg/kg/day
BV/TV 0.262 4.50 -
Cr.S.Dn 0.0414 20.35 -
Ac.fyear 0.21 0.70 -
*
Three year experimental data are available for only the 0.20 mg/kg/day and 1.00 mg/kg/day ALN treatments (Allen and Burr, 2007).
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